Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2000

View Archived Issues

Kyowa Hakko discloses new MAbs for treating or diagnosing inflammatory, autoimmune disorders

New drug for hepatitis B and C discovered in China

Karo Bio completes acquisition of Novalon

FDA approves Cafcit oral solution for treatment of AOP

Endovasc obtains funding to advance preclinical testing of NRA

Anti-HCV ribozyme well tolerated in volunteers; studies in chronically infected patients begin

Novirio receives NIAID grant to further R&D of anti-HBV drugs

New antiplatelet agents with pyrrolidinone structure described by Boehringer Ingelheim

Research group at SB focuses on Tie2 modulators

Sanofi-Synthelabo designs new PDE5 inhibitors, as reported in recent patent

Prostaglandin receptor ligands useful for pain and inflammation

New agents for HCV infections under study at AxyS

PF-1201: new antitumor antibiotic selective for tumor gene-transformed cell lines

ISOLDE trial results support use of inhaled corticosteroids in COPD

Taiho discovers naturally occurring substance with potential in periodontal diseases

Actelion announces results from phase III trial in pulmonary hypertension

SB-219383: a novel bacterial tyrosyl-tRNA synthetase inhibitor produced by Micromonospora

Bayer presents new PDE inhibitor in development for COPD and asthma

Antiplatelet effects of green tea and a major component discussed in Porto

Survival results promising in phase II study of 81C6 MAb in patients with recurrent brain tumors

Vanguard calls off merger discussions with CeNeS

Hepatitis C combination therapy launched in Spain

Marketed anticonvulsant as a new option for painful diabetic neuropathy

Remune pivotal clinical trial initiated for treatment of HIV infection

Medinox and Fuso to collaborate on development of new NO-neutralizing drug

Isolation, structure and biological activity of new Cdc25B tyrosine phosphatase inhibitors

Important drug warning issued for Herceptin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...